studiedDrug

47 triples

GPTKB property

testedDrug

Subject	Object
gptkb:TRANSCEND_trial	gptkb:telmisartan
gptkb:Canakinumab_Anti-inflammatory_Thrombosis_Outcomes_Study	gptkb:canakinumab
gptkb:JUPITER_trial	gptkb:rosuvastatin
gptkb:COVID-19_Solidarity_Trial_(WHO)	gptkb:interferon_beta-1a
gptkb:CheckMate_227	gptkb:nivolumab
gptkb:RE-LY_trial	gptkb:dabigatran
gptkb:CheckMate_227	gptkb:ipilimumab
gptkb:PolyHeme_Phase_III_Clinical_Trial	gptkb:PolyHeme
gptkb:IMpower150	gptkb:bevacizumab
gptkb:COVID-19_Solidarity_Trial_(WHO)	hydroxychloroquine
gptkb:Adaptive_COVID-19_Treatment_Trial_1	gptkb:remdesivir
gptkb:Solidarity_trial	gptkb:interferon_beta-1a
gptkb:Adaptive_COVID-19_Treatment_Trial_1	placebo
gptkb:JULIET_trial	gptkb:tisagenlecleucel
gptkb:KEYNOTE-024:_Pembrolizumab_versus_Chemotherapy_for_PD-L1–Positive_Non–Small-Cell_Lung_Cancer	gptkb:pembrolizumab
gptkb:SURPASS-2	gptkb:tirzepatide
gptkb:ECHO-301/KEYNOTE-252_trial	gptkb:epacadostat
gptkb:IMpower150	gptkb:atezolizumab
gptkb:ECHO-301/KEYNOTE-252_trial	gptkb:pembrolizumab
gptkb:IMpower150	paclitaxel